Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

May 28, 2007

SRV in non responders

Analysis of: "Triple Anti-HCV Drug Therapy for Nonresponders to Peginterferon/Ribavirin: Interferon Gamma (Actimmune) + Ribavirin + Pegasys or Infergen: A Pilot Study" | www.natap.org
This analysis is solely the work of the author. It has not been edited or endorsed by GLG.
Analysis By:
Dipti Doshi, MD
Rheumatologist, HEALTHCARE PARTNERS MEDICAL GROUP
Implications: Very nice article. Although sample size seemed very less, avaialble results look very promising. Particularly in contrast of Leevy study. Only concern is of side-effects. Would make things clear on further study with the same drug

Analysis: Promising treatment modality-but needs lot of further trials before any conclusion can even be drawn.

Other Analyses of the Same Source Article:
triple therapy study design flawed
September 21, 2007, Author: GLG Expert Contributor
Still, it might provide only temporal improvement and is not solving the problem
June 4, 2007, Author: GLG Expert Contributor
Short revision
May 28, 2007, Author: GLG Expert Contributor

Report a Concern

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-10-12T05:45:20.590